Healthcare Utilization and Economic Burden of Cardiomyopathy in China

NCT06893731 | Enrolling By Invitation DMC

• 1 other identifier: 2023-ZX005
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, and it has a huge psychological and economic burden on family members. In this study, the investigators collected clinical information and costs of patients hospitalized with cardiomyopathy and establish a database to evaluate the economic burden of cardiomyopathy.

Conditions

Cardiomyopathies; Economic Burden

Outcome Measures

Primary Outcomes (1)

• total cost per hospital admission

  Total cost per hospital admissionin is total expenditures made towards a given hospital admission, including the portion paid by the health plan and any out-of-pocket costs paid by enrollees under the plan's cost sharing.The composition of the total cost of hospitalization by categorizing itemized costs into the following groups: total medical consumables cost, total diagnosis-related cost, total treatment cost (e.g., cost of operation), total Western medicine cost, total services cost, total blood and blood products cost, total traditional Chinese medicine cost, total traditional Chinese treatment cost, total rehabilitation cost, and other costs.

  through hospitalization completion, an average of 10 days

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients hospitalized with cardiomyopathy as the primary discharge diagnosis are recruited retrospectively from multiple centers in China between March 1, 2017 and March 1, 2022.

You may qualify if:

• Hospitalized patients with primary discharge diagnosis meeting one of the following subtypes of cardiomyopathy were enrolled, including HCM, DCM, ACM, RCM, left ventricular non-compaction, cardiac amyloidosis, Fabry disease, Pompe disease, Danon disease, and PRKAG2 cardiac syndrome.

You may not qualify if:

• none

Sponsors & Collaborators

• China National Center for Cardiovascular Diseases: lead

Study Sites (1)

Fuwai hospital, Beijing, Beijing 100037

Beijing, China

Location

MeSH Terms

Conditions

Cardiomyopathies; Financial Stress

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases; Stress, Psychological; Behavioral Symptoms; Behavior

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator, Clinical Professor

Study Record Dates

• First Submitted: September 27, 2024
• First Posted: March 25, 2025
• Study Start: March 1, 2017
• Primary Completion: March 1, 2022
• Study Completion: April 1, 2026
• Last Updated: April 17, 2025

Record last verified: 2024-09

Locations

CN (1)